Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACAD 
ACADIA Pharmaceuticals Inc (ACAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: ACAD (3-star) is a STRONG-BUY. BUY since 44 days. Profits (31.41%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $28.47
1 Year Target Price $28.47
| 7 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.16% | Avg. Invested days 46 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.77B USD | Price to earnings Ratio 16.46 | 1Y Target Price 28.47 |
Price to earnings Ratio 16.46 | 1Y Target Price 28.47 | ||
Volume (30-day avg) 20 | Beta 0.65 | 52 Weeks Range 13.40 - 25.23 | Updated Date 07/16/2025 |
52 Weeks Range 13.40 - 25.23 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.97% | Operating Margin (TTM) 7.9% |
Management Effectiveness
Return on Assets (TTM) 5.56% | Return on Equity (TTM) 37.24% |
Valuation
Trailing PE 16.46 | Forward PE 49.75 | Enterprise Value 3037979918 | Price to Sales(TTM) 3.79 |
Enterprise Value 3037979918 | Price to Sales(TTM) 3.79 | ||
Enterprise Value to Revenue 3.05 | Enterprise Value to EBITDA 29.88 | Shares Outstanding 167362000 | Shares Floating 114821945 |
Shares Outstanding 167362000 | Shares Floating 114821945 | ||
Percent Insiders 0.57 | Percent Institutions 105.53 |
Upturn AI SWOT
ACADIA Pharmaceuticals Inc
Company Overview
History and Background
ACADIA Pharmaceuticals Inc. was founded in 1993. Initially focused on drug discovery using innovative technologies, it transitioned to developing and commercializing treatments for central nervous system disorders. A key milestone was the FDA approval of Nuplazid (pimavanserin) in 2016 for Parkinson's disease psychosis.
Core Business Areas
- Neurology: Focuses on developing and commercializing therapies for neurological disorders. Their main product is NUPLAZID for Parkinson's disease psychosis.
- Psychiatry: Focuses on developing and commercializing therapies for psychiatric disorders. They are exploring new indications for NUPLAZID and other potential products.
Leadership and Structure
The company is led by Steve Davis (CEO). The organizational structure consists of research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- NUPLAZID (pimavanserin): NUPLAZID is an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). While specific market share data is difficult to obtain precisely, it is the dominant treatment for PDP. Revenue from NUPLAZID is the primary revenue driver for ACADIA. Competitors include off-label use of typical and atypical antipsychotics, which have significant safety concerns in the elderly Parkinson's population.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The CNS market is characterized by unmet needs and opportunities for innovative therapies.
Positioning
ACADIA is a specialty pharmaceutical company focused on CNS disorders. Its competitive advantage lies in its approved therapy, NUPLAZID, and its pipeline of potential treatments for underserved populations.
Total Addressable Market (TAM)
The TAM for treatments of psychosis and other CNS disorders is substantial, estimated to be in the billions of dollars. ACADIA is positioned to capture a significant portion of this TAM, particularly with expansion into new indications.
Upturn SWOT Analysis
Strengths
- FDA-approved product (NUPLAZID)
- Strong focus on CNS disorders
- Expanding pipeline of potential therapies
- Specialized sales force targeting neurologists and psychiatrists
Weaknesses
- Reliance on a single product (NUPLAZID) for revenue
- Potential for generic competition
- Risk associated with clinical trials
- Negative publicity surrounding historical data analysis
Opportunities
- Expansion of NUPLAZID into new indications (e.g., dementia-related psychosis)
- Acquisition or licensing of new CNS therapies
- Partnerships with other pharmaceutical companies
- Growing awareness of CNS disorders and unmet needs
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles and delays
- Pricing pressures and reimbursement challenges
- Adverse events or safety concerns related to NUPLAZID
Competitors and Market Share
Key Competitors
- JAZZ
- TEVA
- MYL
Competitive Landscape
ACADIA has a strong position in Parkinson's disease psychosis with NUPLAZID. However, it faces competition from companies with broader CNS portfolios and generic manufacturers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by the sales growth of NUPLAZID.
Future Projections: Future growth is dependent on expansion of NUPLAZID into new indications and the success of pipeline candidates. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include clinical trials for new indications of NUPLAZID and development of other CNS therapies.
Summary
ACADIA Pharmaceuticals is primarily fueled by NUPLAZID sales, offering a unique treatment for Parkinson's disease psychosis. While the company shows revenue growth, profitability remains a concern. Expansion into new indications and successful pipeline development are crucial for future success. Competition and regulatory risks need to be carefully managed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Company Website
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary. Financial data is subject to change. The AI-based rating is generated using available information and should be interpreted with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-05-27 | CEO & Director Ms. Catherine E. Owen Adams | ||
Sector Healthcare | Industry Biotechnology | Full time employees 653 | Website https://www.acadia.com |
Full time employees 653 | Website https://www.acadia.com | ||
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.